In melanoma, inhibition of FTO suppresses tumorigenicity and increases the m6A levels in PD-1, CXCR1, and SOX10, hence enhancing the decay of these m6A-targeted mRNAs by YTHDF2. The gene discussed is YTHDF2; the disease is melanoma.